American Association for Cancer Research
Browse

Figure S4 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

Download (388.63 kB)
journal contribution
posted on 2023-04-04, 02:05 authored by Christianne Groeneveldt, Jurriaan Q. van Ginkel, Priscilla Kinderman, Marjolein Sluijter, Lisa Griffioen, Camilla Labrie, Diana J.M. van den Wollenberg, Rob C. Hoeben, Sjoerd H. van der Burg, Peter ten Dijke, Lukas J.A.C. Hawinkels, Thorbald van Hall, Nadine van Montfoort

Figure S4. TGF-β blockade does not impair Reo&CD3-bsAb efficacy by decreasing T-cell influx or activation.

Funding

Leids Universitair Medisch Centrum (LUMC)

KWF Kankerbestrijding (DCS)

Stichting Overleven met Alvleesklierkanker

NWO | Stichting voor de Technische Wetenschappen (STW)

Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)

ZonMw (Netherlands Organisation for Health Research and Development)

History

ARTICLE ABSTRACT

Blockade of the pleiotropic molecule TGF-β can both improve and impair the efficacy of viro-immunotherapy, depending on the tumor model. While TGF-β blockade antagonized Reo&CD3-bsAb combination therapy in the KPC3 model for pancreatic cancer, it resulted in 100% complete responses in the MC38 colon model. Understanding factors underlying this contrast is required to guide therapeutic application.

Usage metrics

    Cancer Research Communications

    Categories

    Keywords

    ImmunologyTumor immunology animal modelsImmune responses to cancerTumor MicroenvironmentImmune cells and the microenvironmentInflamation and the microenvironmentGastrointestinal CancersPancreatic cancerColorectal cancerImmunotherapyAntibody immunotherapy

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC